title: Quinolones for short-term treatment of uncomplicated urinary tract infection.
abstract: OBJECTIVE
  To investigate whether quinolones produce in vivo responses comparable to reported in vitro activity against the spectrum of organisms in uncomplicated urinary tract infection (UTI) in Nigeria.
  
  
  METHODS
  Equal numbers of patients with urine culture positive UTI were randomized to oral quinolone, perfloxacin 400 mg bd twice a day and ofloxacin 200 mg bd twice a day for five days.
  
  
  METHODS
  Out-patient clinics and wards at the University College Hospital, Ibadan.
  
  
  METHODS
  Sixty patients aged sixteen years and above with uncomplicated UTI.
  
  
  METHODS
  Number of isolates, number of patients with clinical and bacteriological cure one week after commencing therapy. Relative effectiveness and side effects of the drugs.
  
  
  RESULTS
  Sixty- four bacterial isolates were obtained with the enterobacteriaceae comprising 86%. Sixty-two (97%) were sensitive to both drugs in vitro. Clinical cure occurred in 57 patients (95%), being 28 (93%) in those taking perfloxacin and 29 (97%) in those taking ofloxacin. Bacteriological cure occurred in 55 patients (92%), being 27 (90%) in those taking perfloxacin and 28 (93%) in those taking ofloxacin. Fifty-nine of the 64 isolates (92%) were eliminated in one week, 30 of 33 (91%) in those taking perfloxacin, and 29 of 31 (94%) in those taking ofloxacin; the difference was insignificant (p = 1.16). The enterobacteriaceae were generally susceptible to both drugs. Side effects were minor and infrequent.
  
  
  CONCLUSIONS
  Quinolones were highly active against the common urinary pathogens in these Nigerian patients and can be reliably employed in treatment when culture results are unavailable.
authors.affiliation: Department of Medicine, University College Hospital, Ibadan, Nigeria.
authors.forename: S
authors.initials: S
authors.lastname: Kadiri
authors.forename: S O
authors.initials: SO
authors.lastname: Ajayi
authors.forename: R A
authors.initials: RA
authors.lastname: Toki
mesh_terms: D042462:4-Quinolones; D000284:Administration, Oral; D000328:Adult; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology / Q000652:urine; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009549:Nigeria; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D016037:Single-Blind Method; D013997:Time Factors; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology / Q000652:urine; D015366:Pefloxacin
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015242:Ofloxacin; D015366:Pefloxacin